Azurity Pharmaceuticals (“Azurity”) announces the successful completion of its acquisition of Covis Group S.à r.l. (“Covis”) from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity. This strategic acquisition reinforces Azurity’s leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. “QHP Capital is proud to support Azurity in this acquisition, which aligns with our commitment to investing in life sciences and healthcare innovations,” said Jeff Edwards, Partner at QHP Capital, the majority owner of Azurity.
Read the full article: Azurity Pharmaceuticals Completes Acquisition of Covis Pharma //
Source: https://www.prnewswire.com/news-releases/azurity-pharmaceuticals-completes-acquisition-of-covis-pharma-302401898.html